GSK · GSK Plc ADR
United States · RS rating 31 · As of 2026-10-14
| Price | 47.87 USD |
|---|---|
| 1-day change | +3.5% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 40 / 33 / 62 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 27 / 33 |
| Industry group (rank) | Medical-Diversified (32) |
| EPS growth Q/Q | -68.2% |
| Sales growth Q/Q | +0.8% |
| Distance from 52-week high | +21.8% |
| Market cap (USD) | $111.0B |